Trials / Completed
CompletedNCT04252339
RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1, Open Label, Dose Escalation and Expansion Study of RLY-1971, a Highly Potent and Selective SHP2 Inhibitor, in Subjects With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, open-label, dose escalation and expansion study of RLY-1971 in subjects with advanced or metastatic solid tumors.
Detailed description
Dose escalation/dose expansion study to assess the MTD, safety, tolerability, PK and preliminary anti-tumor activity of RLY-1971. Approximately 70 patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RLY-1971 | RLY-1971 is an oral inhibitor of SHP2. |
Timeline
- Start date
- 2020-02-04
- Primary completion
- 2022-11-22
- Completion
- 2022-11-22
- First posted
- 2020-02-05
- Last updated
- 2023-01-31
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04252339. Inclusion in this directory is not an endorsement.